Metformin has been studied in breast cancer, but its mechanism of action in the clinical arena remains unclear. Several trials have attempted to address this knowledge gap (Table [1](#Tab1){ref-type="table"}) \[[@CR1]--[@CR10]\]. In a recent issue of *Breast Cancer Research*, Dowling and colleagues \[[@CR10]\] present their mechanistic studies from a previously reported single arm, neoadjuvant, window of opportunity trial of metformin in non-diabetic breast cancer patients. Thirty-nine operable breast cancer patients were given metformin 500 mg three times daily for a median of 18 days (range 13 to 40). Their results demonstrate that short-term administration of metformin in this setting has anti-cancer properties significantly involving indirect actions of metformin.Table 1Metformin trials in non-diabetic breast cancer patientsStudy/referenceNumber of womenStudy populationSettingDesignMetformin dosingWeightSerum glucoseSerum insulinHOMAProliferation (Ki-67)ApoptosisInsulin-dependent actions of metformin (indirect)Insulin-independent actions of metformin (direct)Goodwin *et al.* 2008 \[[@CR1]\]22Early BC patients; insulin \>45 pmol/LAdjuvantSingle arm500 mg tid × 6 mos↓**○**↓↓Hadad *et al.*, 2011 \[[@CR2]\], Hadad *et al*. 2015 \[[@CR3]\]8 + 47Operable invasive BCNeoadjuvant windowMetf versus ctrl (no metf)500 mg qd × 1 wk, then 1000 mg bid × 1 wk○ in metf, ↑ in ctrl↓ in metf, ○ in ctrl↓Cleaved Caspase-3NS ↓ IR; ↓ pAkt↑p-AMPKBonanni *et al.* 2012 \[[@CR4]\], Cazzaniga *et al.* 2013 \[[@CR5]\], DeCensi *et al.* 2014 \[[@CR6]\]200Operable BCNeoadjuvant windowMetf versus ctrl (placebo)850 mg bid × 4 wks↓ in BMI \> 27NS ↓ in BMI \> 27○ metf versus ctrl; NS ↓ in HOMA \> 2.8 and NS ↑ in HOMA \< 2.8TUNEL ↑ in both metf and ctrl↓IGFBP-1Kalinsky *et al.* 2014 \[[@CR7]\]35Ov/Ob invasive BC or DCIS versus matched untreated historical ctrlNeoadjuvant windowSingle arm500 mg am and 1000 mg pm, 2--4 wks (avg = 22 days)↓○NS ↓NS ↓○○ IGFBP-3Goodwin *et al.* 2015 \[[@CR8]\]3,649Treated early BCAdjuvantMetf versus ctrl (placebo)850 mg bid × 5 yrs (results reported after 6 mos)↓↓↓↓Niraula *et al*. 2012 \[[@CR9]\], Dowling *et al.* 2015 \[[@CR10]\]39Operable BCNeoadjuvant windowSingle arm500 mg tid 13--40 days (avg = 18)↓↓NS ↓↓Largest ↓ in patients with largest ↓ in insulin, IR, and pAktTUNEL ↑↓ IR, pAkt, and pERK1/2↓ pAMPK and pACC; all tumors expressed OCT1Down arrows indicate decrease; circles indicate no change; up arrows inidcate increase. ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; avg, average; BC, breast cancer; bid, twice a day; BMI, body mass index; ctrl, control; DCIS, ductal carcinoma *in situ*; ERK, extracellular signal-regulated protein kinase; HOMA, homeostatic model assessment; IGFBP, insulin-like growth factor-binding protein; IR, insulin receptor; metf, metformin; mos, months; NS, non-significant; Ob, obese; OCT, organic cation transporter; Ov, overweight; qd, once a day; tid, three times a day; TUNEL, terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling; wks, weeks; yrs, years

By binding to its receptor, insulin has been shown to have mitogenic and anti-apoptotic effects in several cancers, including breast cancer, and circulating insulin is associated with increased cancer risk and prognosis \[[@CR11]\]. In their previous publication on the same trial \[[@CR9]\], the authors reported significant decreases in weight, body mass index (BMI), glucose, homeostatic model assessment (HOMA), and tumor cell proliferation by Ki-67, as well as an increase in apoptosis by TUNEL (terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling) after metformin treatment. In the current study, they point to the insulin-dependent effects of metformin based on the decrease in insulin receptor (IR) expression in tumors together with reductions in Akt and ERK1/2 phosphorylation (key downstream effectors of phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K)/Akt and Ras-mitogen-activated protein kinase (MAPK) signaling pathways, respectively). Furthermore, in an important analysis, when patients were assessed individually, the largest decreases in serum insulin, tumor IR, and p-Akt (via a summary score of all three variables) correlated with the largest decreases in tumor cell proliferation. However, overall changes in Akt and ERK1/2 phosphorylation did not correlate with reductions in circulating insulin levels, suggesting that these changes were also mediated by additional (unexplored) insulin-independent pathways.

The decreases in Akt and ERK1/2 phosphorylation are in agreement with previous *in vitro* and *in vivo* breast cancer studies \[[@CR12], [@CR13]\]. Likewise, the decreases in IR expression and p-Akt are consistent with a two arm window of opportunity trial conducted by Bonanni and colleagues \[[@CR4]\], where non-diabetic women with breast cancer were randomized to metformin or no drug. In that study, a non-significant decrease in IR and a significant decrease in p-Akt were found in the metformin group, while non-significant increases were found in the control group. In future studies, it would be interesting to analyze activated (phosphorylated) IR staining in tumors to further define the role of this signaling axis.

Metformin can also exert its anti-tumor activity through insulin-independent direct actions on cancer cells. The most studied pathway involves the serine/threonine kinase AMP-activated protein kinase (AMPK), a metabolic master switch which is activated in low energy states. Upon activation, AMPK increases cellular energy levels by inhibiting energy-consuming anabolic pathways and stimulating energy-producing catabolic pathways. The role of AMPK in tumorigenesis is the subject of ongoing investigation. Metformin has been shown to activate AMPK in both cancer and non-cancer settings. This includes a window of opportunity trial by Hadad and colleagues \[[@CR3]\], where treated patients showed significant upregulation of p-AMPK compared with the control group. In the current study, contrary to expectation, the authors found a decrease in the activation of AMPK and one of its targets (acetyl-CoA carboxylase(ACC)) upon treatment with metformin, as well as a high baseline level of AMPK. A similar result was obtained in a window of opportunity study in endometrial cancer \[[@CR14]\]. The explanation for this paradoxical result is unclear. However, it is known that metformin may have both AMPK-dependent and AMPK-independent anti-tumor effects in different contexts \[[@CR15]\]. AMPK-independent effects were not examined in the current study and should be the subject of future investigations of the direct effects of metformin in breast cancer.

The current study has a number of strengths. Metformin was administered as close as possible to the time of tumor tissue acquisition, which may be critical for accurate measurement of biomarkers. The analysis in individual patients to correlate several biomarkers (serum insulin, and tumor IR and p-Akt, with tumor Ki-67) is a compelling one. Limitations include small sample size and lack of no treatment controls, so that the results will need to be validated in larger trials. The study suggests some additional analyses to keep in mind for future trials. The pharmacology of metformin in the cancer setting is largely unexplored. It would be interesting to see whether dividing the wide range of metformin treatment time (13 to 40 days) into groups of shorter and longer duration or into high versus low OCT1 expression levels would reveal differences in biomarkers according to these parameters.

In summary, in combination with the results from the trials listed in Table [1](#Tab1){ref-type="table"}, the results of Dowling *et al*. strongly suggest that metformin exerts a significant part of its anti-tumor effects in breast cancer via the indirect pathway by lowering serum insulin, inhibiting downstream signaling via PI3K/Akt and Ras-MAPK pathways, and leading to decreases in cell proliferation. This information has important implications for the conduct and analysis of ongoing and future clinical trials of metformin. A number of trials are currently underway evaluating metformin in breast cancer (clinicaltrials.gov). The largest and most advanced is the NCIC CTG MA.32, an ongoing adjuvant trial of 3,649 women with early stage breast cancer examining the effects of metformin versus placebo on survival and other outcomes. An initial report has been published showing that metformin significantly improved metabolic parameters such as weight, insulin, glucose, leptin, and C-reactive protein (CRP) at 6 months, regardless of initial weight or degree of insulin resistance \[[@CR8]\]. The results of the current study suggest that serum insulin and tumor IR, p-Akt, and Ki-67 should be evaluated as potential biomarkers of metformin tumor sensitivity in this and other metformin trials in breast cancer. The role of the direct effects of metformin on breast cancer cells, whether mediated via AMPK or otherwise, remains an open question to be explored in future pre-clinical and clinical studies. These and other studies will undoubtedly contribute to the evolving mystery of this fascinating drug.
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See related research by Dowling *et al.*, <http://breast-cancer-research.com/content/17/1/32>.
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